Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) reported EBT Margin of 135.29% for Q1 2026, down 2738.0% year-over-year from 5.13% in Q1 2025, and down 119.63% quarter-over-quarter from 61.6% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 11 years of EBT Margin data on file, last reported at 135.29% in Q1 2026.
- EBT Margin for Q1 2026 came in at 135.29%, down 2738.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 90.37% (down 9312.0% YoY), and the FY2025 annual result was 84.84%, down 8413.0% from the prior year.
- EBT Margin slipped to 135.29% in Q1 2026 per RARE's latest filing, from 61.6% in the prior quarter.
- Over five years, EBT Margin peaked at 261.28% in Q4 2024 and troughed at 263.3% in Q3 2022.
- A 5-year average of 112.66% and a median of 135.29% in 2026 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin jumped 36150 bps in 2024, then plunged 32288 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 148.32% in 2022, then jumped by 32 bps to 100.22% in 2023, then jumped by 361 bps to 261.28% in 2024, then sank by 124 bps to 61.6% in 2025, then sank by 120 bps to 135.29% in 2026.
- Business Quant data shows RARE's EBT Margin at 135.29% in Q1 2026, 61.6% in Q4 2025, and 112.26% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | -135.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -135.29% |
| Dec 31, 2025 | -61.60% |
| Sep 30, 2025 | -112.26% |
| Jun 30, 2025 | -68.47% |
| Mar 31, 2025 | -107.91% |
| Dec 31, 2024 | 261.28% |
| Sep 30, 2024 | -95.50% |
| Jun 30, 2024 | -88.92% |
| Mar 31, 2024 | -156.41% |
| Dec 31, 2023 | -100.22% |
| Sep 30, 2023 | -162.16% |
| Jun 30, 2023 | -146.89% |
| Mar 31, 2023 | -162.67% |
| Dec 31, 2022 | -148.32% |
| Sep 30, 2022 | -263.30% |
| Jun 30, 2022 | -176.69% |
| Mar 31, 2022 | -189.86% |
| Dec 31, 2021 | -149.63% |
| Sep 30, 2021 | -89.18% |
| Jun 30, 2021 | -140.23% |